Russian Medicine Makes Breakthrough in New Treatment for Psoriasis in Schoolchildren

Efleyra, a Russian-developed medication, has received approval for expanded use in treating children and adolescents suffering from moderate to severe plaque psoriasis. This marks a significant advancement, as the drug, also known as netakimab, was previously available only to adults battling severe forms of psoriasis and psoriatic arthritis. Clinical Trial Demonstrates Efficacy in Younger Patients To validate Efleyra's safety and effectiveness in pediatric patients, Biocad, the pharmaceutical company behind the drug, conducted a Phase III clinical trial. The study enrolled 155 participants between the ages of 6 and 17. After a 12-week treatment period, the results showed Efleyra significantly outperformed a placebo in key measures of efficacy. Researchers observed that the treatment's positive effects were consistent across the board, unaffected by a patient's age, body weight, or the initial severity of their condition. This suggests a broad applicability of the drug within the younger demographic.